EVMN

Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Wall Street analysts forecast EVMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVMN is 39.33 USD with a low forecast of 36.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Evommune Inc revenue for the last quarter amounts to 100.00 USD, decreased 0.00 % YoY.

Evommune Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Evommune Inc (EVMN) has 0 emplpoyees as of January 07 2026.

Today EVMN has the market capitalization of 512.90M USD.